Dupilumab-Improved Lung Function Lasts in Children With Asth

Add-on treatment with dupilumab may improve lung function in children aged 6-11 years with uncontrolled moderate to severe type 2 inflammatory asthma, results from a phase 3 study show.

Related Keywords

United States , Houston , Texas , Baylor College Of Medicine , American , Muhammad Adrish , Monroe Carell Jr , Leonardb Bacharier , Regeneron Pharmaceuticals , Glaxosmithkline , Drug Administration , Cf Foundation , American Thoracic Society International Conference , Airways Disorders Network Steering Committee , American College Of Chest Physicians , Astrazeneca , Children Hospital At Vanderbilt University Medical Center , Monroe Carell , Vanderbilt University Medical Center , American College , Chest Physicians , Baylor College , Disorders Network Steering Committee , Biologics License Application , Asthma , Sthmatic , Children , Child , Childhood , Ediatrics , Kids , Adhd , Attention Deficit Hyperactivity Disorder , Ttention Deficit Hyperactivity Disorder Adhd , Attention Deficit Disorder Add , Attention Deficit Disorder , Odd , Childhood Asthma , Fev1 , Severe Asthma , Pulmonary Eosinophilia , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Lung , Thoracic Region Of Chest , Oche ,